Thomas C. Wright,

Thomas C. Wright,'s AcademicInfluence.com Rankings

Thomas C. Wright,

Medical

#3356

World Rank

#3824

Historical Rank

Public Health

#527

World Rank

#544

Historical Rank

Epidemiology

#638

World Rank

#664

Historical Rank

medical Degrees

Download Badge

Medical

Thomas C. Wright,'s Degrees

PhD Epidemiology University of California, Berkeley
Masters Public Health University of California, Berkeley
Bachelors Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Thomas C. Wright, Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Thomas C. Wright,'s Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. (2010) (2119)
2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. (2002) (994)
2001 Consensus Guidelines for the management of women with cervical cytological abnormalities (2002) (732)
Cost-effectiveness of cervical-cancer screening in five developing countries. (2005) (673)
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. (2004) (577)
The carcinogenicity of human papillomavirus types reflects viral evolution. (2005) (565)
2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. (2007) (521)
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening (2004) (519)
Incidence of cervical squamous intraepithelial lesions in HIV-infected women. (2000) (517)
HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. (2000) (491)
Guidelines for preventing opportunistic infections among HIV-infected persons - 2002 (2002) (474)
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. (2011) (449)
Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. (2001) (396)
Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. (2015) (387)
2006 Consensus Guidelines for the Management of Women With Abnormal Cervical Screening Tests (2007) (358)
Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. (2005) (355)
Human papillomavirus infection in women infected with the human immunodeficiency virus. (1998) (351)
2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. (2007) (350)
High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. (2011) (316)
Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. (2002) (279)
Evaluation of alternative methods of cervical cancer screening for resource‐poor settings (2000) (275)
Adding a test for human papillomavirus DNA to cervical-cancer screening. (2003) (270)
Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. (2005) (253)
Human Papillomavirus Infection in Women Infected with the Human Immunodeficiency Virus (1997) (250)
2006 Consensus Guidelines for the Management of Women With Cervical Intraepithelial Neoplasia or Adenocarcinoma In Situ (2007) (247)
Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More (2004) (229)
A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine (2003) (229)
The ATHENA human papillomavirus study: design, methods, and baseline results. (2012) (228)
2001 Consensus guidelines for the management of women with cervical intraepithelial neoplasia. (2003) (228)
Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: Prevalence, risk factors, and validity of papanicolaou smears (1994) (227)
Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. (1994) (225)
Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. (1999) (222)
Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. (2011) (213)
Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. (2000) (213)
The 2001 Bethesda System terminology. (2003) (200)
Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. (2005) (199)
Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. (2013) (195)
Precancerous Lesions of the Cervix (1994) (193)
Comparison of Management Algorithms for the Evaluation of Women With Low‐Grade Cytologic Abnormalities (1995) (184)
HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study (2002) (179)
The uniform approach to breast fine-needle aspiration biopsy. National Cancer Institute Fine-Needle Aspiration of Breast Workshop Subcommittees. (1997) (176)
Human Papillomavirus Infection in Human Immunodeficiency Virus–Seropositive Women (1995) (169)
Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis. (1992) (162)
Treatment of Cervical Intraepithelial Neoplasia Using the Loop Electrosurgical Excision Procedure (1992) (156)
Direct visual inspection for cervical cancer screening (2002) (147)
Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. (2010) (133)
Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. (2004) (128)
Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. (2005) (127)
Cervical human papillomavirus infection and intraepithelial neoplasia: a review. (1996) (127)
Women's desired information about human papillomavirus (2004) (125)
Primary Cervical Cancer Screening With Human Papillomavirus: End of Study Results From the ATHENA Study Using HPV as the First-Line Screening Test (2015) (120)
Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia. (1992) (119)
Cervical Cancer Screening in the 21st Century: Is it Time to Retire the PAP Smear? (2007) (115)
Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. (1998) (114)
Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. (1994) (109)
Controversies in the management of low‐grade cervical intraepithelial neoplasia (1993) (106)
Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. (2007) (106)
Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women (2010) (103)
The 2001 Bethesda system: Terminology for reporting results of cervical cytology (2002) (99)
Role of human papillomavirus in the pathogenesis of genital tract warts and cancer. (1990) (98)
Acceptability of self-collection of specimens for HPV DNA testing in an urban population. (2005) (97)
Effective cervical neoplasia detection with a novel optical detection system: a randomized trial. (2007) (96)
Molecular biology of cervical cancer and its precursors (1995) (96)
News media coverage of human papillomavirus (2004) (95)
Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. (2006) (93)
Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. (2001) (91)
Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus (1997) (90)
Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. (2017) (88)
Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy? (1998) (88)
Distribution of Human Papillomavirus Genotypes among HIV-Positive and HIV-Negative Women in Cape Town, South Africa (2014) (88)
Direct comparison of liquid‐based and conventional cytology in a South African screening trial (2006) (81)
Alternative approaches to cervical cancer screening for developing countries. (2012) (81)
Clinical Evaluation of the Cartridge-Based GeneXpert Human Papillomavirus Assay in Women Referred for Colposcopy (2014) (77)
Diagnostic performance of Hybrid Capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study. (1996) (76)
Interlaboratory variation in the performance of liquid‐based cytology: Insights from the ATHENA trial (2014) (76)
Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV‐seropositive women (1996) (75)
Carcinoma and Other Tumors of the Cervix (2019) (72)
Characteristics of Menstruation in Women Infected With Human Immunodeficiency Virus (1996) (72)
Conventional cervical cytologic smears vs. ThinPrep smears. A paired comparison study on cervical cytology. (1996) (69)
Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. (2001) (69)
Rapid rise in detection of human papillomavirus (HPV) infection soon after incident HIV infection among South African women. (2011) (69)
Association between human papillomavirus type and clonal status of cervical squamous intraepithelial lesions. (1996) (68)
Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. (1998) (68)
Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix. (2000) (66)
Prevalence of Underlying Adenocarcinoma in Women with Atypical Endometrial Hyperplasia (2005) (64)
Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. (2001) (62)
Two-stage cervical cancer screening: an alternative for resource-poor settings. (2000) (61)
Distinguishing the temporal association between women's intravaginal practices and risk of human immunodeficiency virus infection: a prospective study of South African women. (2006) (60)
APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. (2013) (60)
Dietary intake and blood levels of lycopene: association with cervical dysplasia among non-Hispanic, black women. (1998) (59)
Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. (2015) (58)
Nested Case–Control Study of Cervical Mucosal Lesions, Ectopy, and Incident HIV Infection Among Women in Cape Town, South Africa (2006) (56)
Increased cervical cancer risk associated with screening at longer intervals. (2015) (56)
Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests (2007) (55)
Significance of mild cytologic atypia in women infected with human immunodeficiency virus (1996) (54)
Age considerations when vaccinating against HPV. (2008) (53)
A Polymerase Chain Reaction–Enzyme‐Linked Immunosorbent Assay Method for Detecting Human Papillomavirus in Cervical Carcinomas and High‐Grade Cervical Cancer Precursors (1995) (52)
Intravaginal Practices, HIV and Other Sexually Transmitted Diseases Among South African Women (2004) (51)
The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results. (2018) (48)
Human papillomavirus testing and screening. (2005) (48)
Chapter 14: HPV vaccine introduction in industrialized countries. (2006) (47)
Cervical cancer screening in low‐resource settings: A cost‐effectiveness framework for valuing tradeoffs between test performance and program coverage (2015) (47)
The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study. (2012) (46)
The Effect of HIV and HPV Coinfection on Cervical COX-2 Expression and Systemic Prostaglandin E2 Levels (2011) (45)
The costs of reducing loss to follow-up in South African cervical cancer screening (2005) (44)
Human immunodeficiency virus infection and female lower genital tract malignancy. (1999) (42)
Evaluating HPV‐negative CIN2+ in the ATHENA trial (2016) (42)
Comparison of specimens removed by CO2 laser conization and the loop electrosurgical excision procedure. (1992) (41)
CHAPTER 3 Pathology of HPV infection at the cytologic and histologic levels: Basis for a 2‐tiered morphologic classification system (2006) (41)
Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population. (2015) (41)
Human Papillomavirus (HPV) Detection Among Human Immunodeficiency Virus–Infected Pregnant Thai Women: Implications for Future HPV Immunization (2006) (38)
Treating vaginal and external anogenital condylomas with electrosurgery vs CO2 laser ablation. (1995) (37)
Oral contraceptive and benign ovarian tumors. (2000) (37)
Pearly Penile Papules: Absence of Human Papillomavirus DNA by the Polymerase Chain Reaction (1991) (36)
HPV DNA Testing for Cervical Cancer Screening (2006) (36)
Assessment of the Cervix After Acetic Acid Wash: Inter‐Rater Agreement Using Photographs (2002) (35)
Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens. (2014) (34)
Chapter 10: Cervical cancer screening using visualization techniques. (2003) (34)
Cervical cancer screening using visualization techniques (2003) (34)
Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol. (2004) (32)
Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study. (2015) (31)
Anogenital papillomavirus infection and neoplasia in immunodeficient women. (1996) (31)
Evaluation of the Hybrid Capture human papillomavirus deoxyribonucleic acid detection test. (1995) (31)
Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: a diagnostic accuracy study. (2020) (30)
Use of visual screening methods for cervical cancer screening. (2002) (30)
Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology. (2019) (29)
Invasive vulvar carcinoma in two women infected with human immunodeficiency virus. (1996) (29)
Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology. (2019) (29)
Increased detection of high-grade cervical intraepithelial neoplasia utilizing an optical detection system as an adjunct to colposcopy. (2007) (29)
Low prevalence of human papillomavirus infection of the cervix in renal transplant recipients. (1996) (28)
Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. (2020) (28)
Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki‐67 dual‐stained cytology—Retrospective insights from ATHENA (2019) (27)
HPV vaccine introduction in industrialized countries (2006) (27)
Natural history of HPV infections. (2009) (26)
Clear cell adenosquamous carcinoma of the cervix. An aggressive tumor associated with human papillomavirus‐18 (1995) (26)
X chromosome inactivation and microsatellite instability in early and advanced bilateral ovarian carcinomas. (1995) (26)
Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. (2006) (25)
Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics (2017) (25)
Measuring cervical ectopy: direct visual assessment versus computerized planimetry. (1997) (24)
Distribution of High-Risk Human Papillomavirus Genotypes among HIV-Negative Women with and without Cervical Intraepithelial Neoplasia in South Africa (2012) (24)
A comparison of human papillomavirus testing of clinician‐collected and self‐collected samples during follow‐up after screen‐and‐treat (2011) (23)
Routine Use of Adjunctive p16 Immunohistochemistry Improves Diagnostic Agreement of Cervical Biopsy Interpretation: Results From the CERTAIN Study (2018) (22)
Prevalence of visible disruption of cervical epithelium and cervical ectopy in African women using Depo-Provera. (1999) (22)
Relationships between c-Ki-ras mutations, HPV types, and prognostic indicators in invasive endocervical adenocarcinomas. (1993) (21)
Can cervicography be improved? An evaluation with arbitrated cervicography interpretations. (2002) (21)
Reduced acquisition and reactivation of human papillomavirus infections among older women treated with cryotherapy: results from a randomized trial in South Africa (2010) (20)
Loop excision of the uterine cervix. (1995) (20)
The budget impact of cervical cancer screening using HPV primary screening. (2016) (19)
Human papillomavirus testing in primary cervical screening (1995) (19)
Amplification of the 3q chromosomal region as a specific marker in cervical cancer. (2015) (19)
Knowledge of Patients' Human Papillomavirus Status at the Time of Cytologic Review Significantly Affects the Performance of Cervical Cytology in the ATHENA Study. (2016) (18)
Comparison of CO2 laser surgery and loop electrosurgical excision/fulguration procedure (LEEP) for the treatment of vulvar intraepithelial neoplasia (VIN) (1993) (17)
Recurrence of symptomatic bacterial vaginosis 12 months after oral metronidazole therapy in HIV-positive and -negative women. (2006) (17)
Is viral status needed before vaccination? (2008) (16)
Cigarette smoking and cervical dysplasia among non-Hispanic black women. (1998) (16)
Molecular variants of human papillomavirus type 16 and risk for cervical neoplasia in South Africa (2005) (16)
Detection of Cervical Neoplasia by Human Papillomavirus Testing in an Atypical Squamous Cells-Undetermined Significance Population (2018) (15)
Loop electrosurgical excision procedure for CIN. (1992) (15)
Cervical cancer prevention for all the world's women: New approaches offer opportunities and promise (2007) (15)
Preliminary experimental results from multi-center clinical trials for detection of cervical precancerous lesions using the Cerviscan/spl trade/ system: a novel full-field evoked tissue fluorescence based imaging instrument (2001) (15)
Analysis of lower genital tract lesions clinically suspicious for condylomata using in situ hybridization and the polymerase chain reaction for the detection of human papillomavirus. (1994) (14)
HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial. (2019) (14)
Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico (2016) (13)
Cervical cancer prevention using visual screening methods (1999) (13)
Detection of Infectious Human Immunodeficiency Virus Type 1 in Female Genital Secretions by a Short-Term Culture Method (2003) (13)
2001 Consensus Guidelines for the Management of Women with Cervical Intraepithelial Neoplasia (2003) (12)
Oral Contraceptives and Benign Ovarian Tumors (2001) (12)
Epithelial Cell Abnormalities: Squamous (2015) (12)
HPV DNA testing for cervical cancer screening. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. (2006) (12)
Performance of Xpert HPV on Self-collected Vaginal Samples for Cervical Cancer Screening Among Women in South Africa (2020) (11)
Managing abnormal cytology results in pregnancy. (2005) (11)
Performance of an Human Papillomavirus Test in Samples From Women With Histolopathologically Confirmed Invasive Cervical Cancer (2016) (11)
HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology (2019) (11)
Selecting human papillomavirus genotypes to optimize the performance of screening tests among South African women (2020) (11)
Estradiol-Induced Hyperplasia in Endometrial Biopsies From Women on Hormone Replacement Therapy (2002) (11)
Chlamydia trachomatis and Pap testing from a single, fluid-based sample. A multicenter study. (2001) (10)
Erratum: Cervical cancer control, priorities and new directions (International Journal of Cancer (2003) 108 (329-333)) (2004) (9)
Clinical validation of p16/Ki‐67 dual‐stained cytology triage of HPV‐positive women: Results from the IMPACT trial (2021) (9)
Clonal expansion and HPV-induced immortalization are early molecular alterations in cervical carcinogenesis. (2003) (7)
South African women's perspectives on self-sampling for cervical cancer screening: A mixed-methods study. (2018) (7)
Pathology of the cervix (1991) (7)
Human Immunodeficiency Virus Infection of Early Passage Cervical Epithelial Cultures (1993) (7)
Cervical cancer prevention - a paradigm shift? (2005) (7)
Alliance for cervical cancer prevention: setting the record straight. (2007) (7)
Adjunctive HPV In-Situ Hybridization (ISH) Assay as an Aid in the Diagnosis of Cervical Intraepithelial Neoplasia in Cervical Tissue Specimens: An Analytical and Functional Characterization (2012) (6)
Primary Cervical Cancer Screening With Human Papillomavirus (2015) (6)
PIN37 A COMPREHENSIVE NATURAL HISTORY MODEL OF HUMAN PAPILLOMAVIRUS (HPV) INFECTION AND CERVICAL CANCER: POTENTIAL IMPACT OF AN HPV 16/18 VACCINE (2002) (6)
Atypical glandular cells (AGC): ThinPrep Imaging System (TIS), manual screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing (2009) (6)
Screening for cervical cancer. (2000) (6)
Correlation of Human Immunodeﬁciency Virus Type 1 RNA Levels in Blood and the Female Genital Tract (1999) (5)
Bacterial Vaginosis and Susceptibility to HIV Infection in South African Women: A Nested (2005) (5)
Cervical cancer screening strategies for developing countries. Symposium. (2001) (5)
The IMPACT trial: human papillomavirus, cervical cytology and histopathological results from the baseline and 1-year follow-up phase. (2021) (5)
A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus–positive and -Negative Cervical Precancers (2020) (5)
Prevention of cervical cancer in low-resource settings. Authors' reply (2006) (4)
What you need to know about cervical cancer, genital warts, and HPV (2007) (4)
High-grade uterine sarcoma during pregnancy. (2011) (3)
Infiltrating adenomyosis of the cervix with features of a low-grade stromal sarcoma: a case report and a literature review. (2014) (2)
HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer (2000) (2)
Adjunctive p16 Immunohistochemistry Use in Cervical Biopsies According to LAST Criteria (2021) (2)
The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions. (2002) (2)
Prospects for cervical screening in developing countries (2000) (2)
Cervical cancer screening in non-industrialised countries (2003) (2)
Cytological features of choricarcinoma in a Pap smear: A case report and literature review (2016) (2)
Outpatient surgery in gynecologic oncology (1993) (2)
The New ASCCP Colposcopy Standards. (2017) (1)
B‐cell lymphoma of the vagina occurring after treatment for classic Hodgkin lymphoma: A case report and literature review (2013) (1)
The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase (2021) (1)
Clinical utility of reflex testing with cancer biomarkers to improve diagnostic accuracy of primary Human Papillomavirus screening. (2022) (1)
Loop Electrosurgical Excision Procedure for Treating Cervical Intraepithelial Neoplasia (2011) (1)
Prevention of Cervical Cancer in Low-Resource Settings—Reply (2006) (1)
The CERTAIN Study Results (2021) (1)
Management of Women with High-Grade Squamous Intraepithelial Lesion and Atypical Glandular Cell Cervical Cytology (2006) (1)
Immunosuppression and the Cervix: Human Immunovirus (HIV) (2009) (1)
Risk of ≥ CIN3 after 3 years of follow-up of 42,209 screened women: End of study results from ATHENA (2013) (1)
HPV Testing of Self-Collected Vaginal Swabs for Cervical Cancer Prevention in South Africa (2016) (1)
Preliminary results from multicenter clinical trials for detection of cervical squamous intraepithelial lesions using a novel full-field evoked-tissue-flourescence-based imaging instrument (2001) (1)
A Local and Global Perspective on Cervical Screening with HPV - An Educational Forum (2014) (0)
Nephrology Dialysis Transplantation Low prevalence of human papillomavirus infection of the cervix in renal transplant recipients (2005) (0)
HPV primary screening incorporating genotyping and p16/Ki-67 dual-stained cytology to determine which HPV positive women would benefit from colposcopy (2015) (0)
Comparison of the performance of human papillomavirus (HPV) primary screening strategies with cytology-based strategies: Results from the ATHENA trial 3-year follow-up phase (2014) (0)
HPV Oncogenic mRNA testing for Cervical Cancer Screening ; Baseline and Longitudinal 2 Results from the CLEAR Study 3 4 (2014) (0)
Treatment of CIN using the loop electrodiathermy excision procedure (1991) (0)
Errata (2002) (0)
PCR-Based quantification of replication-competent HIV-1 in female genital secretions (2001) (0)
Errata (2003) (0)
Human papillomavirus. (2019) (0)
Reflex Human Papillomavirus Deoxyribonucleic Acid Testing in Women with Abnormal Papanicolaou Smears (1998) (0)
Diagnosis of adenocarcinoma in situ (AIS): Changing trends and the impact of human papillomavirus (HPV) testing (2014) (0)
Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial. (2023) (0)
The Management of Women with Atypical Squamous Cells (2008) (0)
ARness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy (2005) (0)
Human papillomavirus in adenocarcinomas of the endocervix detected using the polymerase chain reaction (1992) (0)
PCN3 POTENTIAL IMPACT OF WANING OF VACCINE-INDUCED IMMUNITY AGAINST HUMAN PAPILLOMAVIRUS 16/18 (2004) (0)
Use of the Long-Acting Injectable Contraceptive Depo Provera and Integrity of the Cervical Epithelium (1998) (0)
Comparison of CO2 Laser Surgery and Loop Electrosurgical Excision/ Fulguration Procedure for the Treatment of Vulvar Intraepithelial Neoplasia (1994) (0)
Abstract B77: High-risk human papillomavirus genotypes among HIV-negative black women with or without cervical disease in South Africa (2010) (0)
Detection of Ki-ras mutations in endocervical adenocarcinomas by polymerase chain reaction (1992) (0)
HIV Infection in Women (2001) (0)
Performance of an Human Papillomavirus Test in Samples From Women With Histopathologically Confirmed Invasive Cervical Cancer. (2016) (0)
Prevention of cervical cancer in low-resource settings. In reply [letter] (2006) (0)
Editorial: Identifying gaps in the knowledge base underlying cervical cytology guidelines (2002) (0)
HPV DNA positivity and cytologic abnormalities in anal intraepithelial neoplasia of HIV-infected and uninfected women (2007) (0)
PIN18 PROJECTED CLINICAL BENEFITS AND COSTEFFECTIVENESS OF AN HPV 16/18 VACCINE (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Thomas C. Wright,?

Thomas C. Wright, is affiliated with the following schools:

Thomas C. Wright,'s Academic­Influence.com Rankings

Thomas C. Wright,'s Degrees

Similar Degrees You Can Earn

Why Is Thomas C. Wright, Influential?

Thomas C. Wright,'s Published Works

Published Works

What Schools Are Affiliated With Thomas C. Wright,?

Thomas C. Wright,'s AcademicInfluence.com Rankings